Literature DB >> 17409013

Drugs and drug resistance in African trypanosomiasis.

Vincent Delespaux1, Harry P de Koning.   

Abstract

Despite the many decades of use of most of the current trypanocides, we know little of their mode of action. This may in part be because most of these will act on multiple targets once inside the cell, and they derive their selective action on the parasite from selective accumulation by the pathogen. Loss of this capacity for drug uptake by the trypanosome would thus be a major cause for drug resistance. We here discuss the use of current drugs against human and veterinary African trypanosomiasis, the prevalence, causes and mechanisms of drug resistance and new developments in trypanosomiasis therapy such as the introduction of nifurtimox and DB289.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409013     DOI: 10.1016/j.drup.2007.02.004

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  94 in total

Review 1.  Mitochondria and trypanosomatids: targets and drugs.

Authors:  Lianet Monzote Fidalgo; Lars Gille
Journal:  Pharm Res       Date:  2011-09-21       Impact factor: 4.200

2.  New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents.

Authors:  Bruno Demoro; Cynthia Sarniguet; Roberto Sánchez-Delgado; Miriam Rossi; Daniel Liebowitz; Francesco Caruso; Claudio Olea-Azar; Virtudes Moreno; Andrea Medeiros; Marcelo A Comini; Lucía Otero; Dinorah Gambino
Journal:  Dalton Trans       Date:  2011-12-02       Impact factor: 4.390

3.  Symmetrical choline-derived dications display strong anti-kinetoplastid activity.

Authors:  Hasan M S Ibrahim; Mohammed I Al-Salabi; Nasser El Sabbagh; Neils B Quashie; Abdulsalam A M Alkhaldi; Roger Escale; Terry K Smith; Henri J Vial; Harry P de Koning
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

4.  Functional and structural analysis of AT-specific minor groove binders that disrupt DNA-protein interactions and cause disintegration of the Trypanosoma brucei kinetoplast.

Authors:  Cinthia R Millan; Francisco J Acosta-Reyes; Laura Lagartera; Godwin U Ebiloma; Leandro Lemgruber; J Jonathan Nué Martínez; Núria Saperas; Christophe Dardonville; Harry P de Koning; J Lourdes Campos
Journal:  Nucleic Acids Res       Date:  2017-08-21       Impact factor: 16.971

Review 5.  Antiparasitic compounds that target DNA.

Authors:  W David Wilson; Farial A Tanious; Amanda Mathis; Denise Tevis; James Edwin Hall; David W Boykin
Journal:  Biochimie       Date:  2008-03-04       Impact factor: 4.079

6.  Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.

Authors:  Georgina A Holloway; William N Charman; Alan H Fairlamb; Reto Brun; Marcel Kaiser; Edmund Kostewicz; Patrizia M Novello; John P Parisot; John Richardson; Ian P Street; Keith G Watson; Jonathan B Baell
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

7.  First small molecular inhibitors of T. brucei dolicholphosphate mannose synthase (DPMS), a validated drug target in African sleeping sickness.

Authors:  Terry K Smith; Benjamin L Young; Helen Denton; David L Hughes; Gerd K Wagner
Journal:  Bioorg Med Chem Lett       Date:  2009-01-30       Impact factor: 2.823

8.  Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4'-epimerase inhibitors: toward the development of novel therapies for African sleeping sickness.

Authors:  Jacob D Durrant; Michael D Urbaniak; Michael A J Ferguson; J Andrew McCammon
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

9.  Killing of trypanosomatid parasites by a modified bovine host defense peptide, BMAP-18.

Authors:  Lee R Haines; Jamie M Thomas; Angela M Jackson; Brett A Eyford; Morteza Razavi; Cristalle N Watson; Brent Gowen; Robert E W Hancock; Terry W Pearson
Journal:  PLoS Negl Trop Dis       Date:  2009-02-03

10.  Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib.

Authors:  Dietmar Steverding; Xia Wang
Journal:  Parasit Vectors       Date:  2009-07-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.